JP2720165B2 - Glucose electrolyte compounding agent - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a glucose electrolyte combination, particularly when administered via vein to a patient who cannot be administered orally, mixed with other nutrients such as amino acid infusions. It relates to a glucose electrolyte formulation suitable for use.

[Conventional technology]

In order for a living body to maintain its life, it is indispensable to ingest not only the three major nutrients of carbohydrates (sugar, starch, etc.), proteins (amino acids) and fats, but also the five major nutrients to which various inorganic substances and vitamins are added. ing.

Therefore, when it is not possible to take these nutrients orally for some reason, intravenous administration with an infusion preparation containing these nutrients is widely performed.

A single infusion preparation containing all nutrients satisfying this nutritional administration method does not yet exist because of lack of stability between its components, for example, the formation of a precipitate, discoloration due to the Maillard reaction, and the like.

For this reason, at present, several ring-shaped liquid preparations that have been decomposed and prepared are administered in a combination suitable for a patient before administration, and administered as a complete intravenous preparation. In each case, in each case, a compounding agent containing glucose and an electrolyte is used as a basic solution, and an infusion solution such as another amino acid and a fat emulsion necessary for administration is added thereto.

The compounding agent containing glucose and electrolyte, which are the above-mentioned basic solutions, contains phosphorus and calcium in its components, and these components are mixed and contained using substances such as potassium phosphate and calcium gluconate. ,
When heat-sterilized, calcium phosphate precipitates, so that it cannot be used as a basic solution for infusion as it is. In addition, when glucose is contained, there is a disadvantage that the compound is colored when sterilized by heating. For this reason, acid is added to adjust the pH to 4.0 to 5.0.
It is also known that the above-mentioned precipitation and discoloration of calcium phosphate do not occur in the pH range.

Therefore, it is necessary to adjust the pH to 4.0 to 5.0 by adding an acid to the glucose electrolyte compounding agent. Acids that can be used for this purpose include inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid, and organic acids such as lactic acid. Among these, pH adjustment with inorganic acids makes these acids appear in various electrolytes to be contained in the compounding agent. Is included, and therefore, it is not preferable because acidosis may be caused by these inorganic acids. For this reason, organic acids are used for pH adjustment in the current grape or other electrolyte compounding agents.

[Problems to be solved by the invention]

However, since lactic acid is metabolized in the liver, it is known that lactic acid metabolism in the liver decreases during severe hepatic disease patients and bleeding shock, resulting in lactic acidosis, and glucose adjusted with lactic acid during hepatic disease patients and shock is known. It is not preferred to use an electrolyte compounding agent.

Accordingly, an object of the present invention is to provide glucose electrolyte which is highly safe even when used in patients with liver disease or bleeding shock, and which does not cause precipitation and discoloration of calcium phosphate even when subjected to high temperature treatment such as sterilization. It is to provide a compounding agent.

[Means for solving the problem]

The present invention relates to a glucose-electrolyte combination for liver disease patients and bleeding shock patients, wherein the pH is adjusted to 4.0 to 5.0 with acetic acid.

Among the electrolytes that can be used in the present invention, sodium chloride, sodium acetate, etc. as a sodium source, potassium acetate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, etc. as a potassium source, magnesium sulfate, etc., as a magnesium source, and a calcium source, Calcium acetate, calcium gluconate, etc., sodium chloride etc. as a crawl source,
Dipotassium hydrogen phosphate, potassium dihydrogen phosphate and the like can be used as a phosphorus source, and zinc sulfate and the like can be used as a zinc source. These are well known to those skilled in the art.

 Preferred glucose electrolyte compounding agents are shown below.

 The following components are concentrations in the aqueous solution 1.

Glucose 200 to 300 g Sodium 30 to 60 mmol Potassium 20 to 60 mmol Calcium 5 to 10 mmol Magnesium 5 to 10 mmol Zinc 5 to 12 micromol Chlor 5 to 15 mmol Phosphorus 5 to 10 mmol According to the present invention, the above-mentioned glucose electrolyte The formulation (aqueous solution) is adjusted to pH 4.0-5.0 with acetic acid.

(Operation)

In the glucose electrolyte compounding agent according to the present invention,
Since the pH is adjusted to 4.0 to 5.0 with acetic acid, it does not precipitate even after heat sterilization, is stable, does not discolor, and acetic acid is not metabolized only by specific metabolic organs, especially the liver. Since it is used efficiently, it is metabolized in patients other than the liver even when administered to patients with liver disease or patients in shock, and has a very fast metabolism rate and is completely metabolized to water and carbon dioxide.

〔Example〕

 Hereinafter, the present invention will be described with reference to examples.

Example 1 112.5 g of glucose, ZnSO ₄ · 7H ₂ O of 1.3 mg, MgS of 616mg
_{O 4 · 7H 2 O, K} 2 HPO 4 in 627 mg, 175 mg of NaCl, 2235mg of CH ₃ C
OONa · 3H ₂ O, was dissolved CH ₃ COOK and calcium gluconate monohydrate 1065mg of 1256mg to distilled water for injection 300 ml,
Acetic acid was added to adjust the pH to 4.5, and distilled water for injection was further added to make the whole to 400 ml. Place this in a glass vial (700m
l) and heat-sterilized according to the Japanese Pharmacopoeia sterilization method. It did not discolor and did not precipitate.

 The composition of each component in the compounding agent 1 is shown below.

Glucose 281.3g Sodium 48.6 mmol potassium 41 mmol calcium 5.9 mmol magnesium 6.3 mmol zinc 11.3 micromoles crawl 7.5 mmol phosphoric 9 mmol Example 2 120 g of glucose, ZnSO ₄ · 7H ₂ O of 1.3 mg, MgSO of 616 mg ₄
7H ₂ O, 627 mg K ₂ HPO ₄ , 175 mg NaCl, 2235 mg CH ₃ COO
Na · 3H ₂ O, 1256 mg CH ₃ COOK and 466 mg (CH ₃ COO) ₂ C
Dissolve a ・ 2H ₂ in 250 ml of distilled water for injection, add acetic acid and adjust pH
Was adjusted to 4.5 and distilled water for injection was added to make a total of 400 ml
And Thereafter, the same processing as in Example 1 was performed. It did not discolor and did not precipitate.

 The composition of each component in the compounding agent 1 is shown below.

Glucose 300g Sodium 48.6 mmol potassium 41 mmol calcium 6mmol magnesium 6.3 mmol zinc 11.3 micromoles crawl 7.5 mmol phosphoric 9 mmol Example 3 80 g of glucose, ZnSO ₄ · 7H ₂ O of 0.72 mg, MgSO of 616 mg ₄
7H ₂ O, 501 mg K ₂ HPO ₄ , 175 mg NaCl, 2235 mg CH ₃ COO
Na · 3H ₂ O, 1006 mg CH ₃ COOK and 466 mg (CH ₃ COO) ₂ C
Dissolve a ・ 2H ₂ in 250 ml of distilled water for injection, add acetic acid and adjust pH
It was adjusted to 4.5, and distilled water for injection was further added to make the whole 400 ml. Thereafter, the same processing as in Example 1 was performed. It did not discolor and no precipitation occurred.

The composition of each component in the above-mentioned compounding agent 1 is glucose 200 g sodium 48.6 mmol potassium 32.8 カ ル シ ウ ム calcium 6 マ グ ネ シ ウ ム magnesium 6.3 〃 zinc 6.3 micromol chlor 7.5 mmol phosphorus 7.2 〃 [effect of the invention] In the glucose electrolyte compounding agent according to the present invention, acetic acid Therefore, it is metabolized even when administered to a patient with liver disease, and has an excellent effect of not causing precipitation or discoloration.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁶ Identification code Agency reference number FI Technical display location A61K 33/42 A61K 33/42 47/12 47/12 K

Claims (2)

(57) [Claims] (1) A glucose-electrolyte combination for a liver disease patient and a hemorrhagic shock patient, wherein the pH is adjusted to 4.0 to 5.0 with acetic acid. 2. An aqueous solution comprising the following components: glucose 200-300 g / sodium 30-60 mmol / potassium 20-60 mmol / calcium 5-10 mmol / magnesium 5-10 mmol / zinc 5-12 micromol / chlor 5-15 The glucose electrolyte blending agent according to claim 1, containing 5 to 10 mmol / mmol / phosphorus.